Jane Street Group LLC Buys New Position in Chimerix, Inc. (NASDAQ:CMRX)

Jane Street Group LLC purchased a new stake in Chimerix, Inc. (NASDAQ:CMRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 17,872 shares of the biopharmaceutical company’s stock, valued at approximately $62,000.

A number of other institutional investors and hedge funds have also bought and sold shares of CMRX. Rosalind Advisors Inc. bought a new stake in shares of Chimerix in the 4th quarter worth $10,614,000. Marshall Wace LLP boosted its holdings in Chimerix by 1,318.5% during the fourth quarter. Marshall Wace LLP now owns 2,213,940 shares of the biopharmaceutical company’s stock worth $7,705,000 after purchasing an additional 2,057,864 shares during the last quarter. Peapod Lane Capital LLC purchased a new position in Chimerix during the fourth quarter worth about $2,626,000. Connor Clark & Lunn Investment Management Ltd. grew its position in Chimerix by 24.6% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 429,513 shares of the biopharmaceutical company’s stock worth $1,495,000 after purchasing an additional 84,801 shares in the last quarter. Finally, Walleye Capital LLC purchased a new stake in Chimerix in the 4th quarter valued at about $1,362,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CMRX has been the topic of a number of research analyst reports. Wall Street Zen started coverage on Chimerix in a research note on Sunday, May 18th. They issued a “sell” rating on the stock. Wedbush reissued a “neutral” rating and issued a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Jefferies Financial Group restated a “hold” rating and issued a $8.50 price objective (down previously from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. Finally, HC Wainwright reiterated a “neutral” rating and set a $8.55 target price (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Chimerix Price Performance

Shares of CMRX stock opened at $8.54 on Monday. The firm has a market cap of $801.09 million, a P/E ratio of -9.09 and a beta of -0.17. The company has a 50 day moving average of $8.54 and a 200-day moving average of $5.88. Chimerix, Inc. has a 12-month low of $0.75 and a 12-month high of $8.55.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.01. The firm had revenue of $0.06 million for the quarter, compared to the consensus estimate of $0.31 million. As a group, equities analysts expect that Chimerix, Inc. will post -0.99 EPS for the current year.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.